Loading...
58 remdesivir COVID-19 controlled studies, 10 RCTs
41% improvement
for early treatment, RR
0.59
[0.29-1.20]
https://c19early.org/smeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Madan (ES)
66%
0.34 [0.12-0.96]
death
4/112
27/260
Improvement, RR [CI]
Treatment
Control
PINETREE
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
PINETREE
Gottlieb (DB RCT)
72%
0.28 [0.11-0.75]
hosp.
5/279
18/283
PINETREE
Gottlieb (DB RCT)
29%
0.71 [0.37-1.37]
no recov.
43/66
45/60
PINETREE
Gottlieb (DB RCT)
48%
0.52 [0.34-0.79]
no recov.
108/169
132/165
Piccicacco
66%
0.34 [0.01-8.32]
death
0/82
1/90
Piccicacco
30%
0.70 [0.28-1.72]
hosp.
7/82
11/90
Piccicacco
52%
0.48 [0.21-0.96]
hosp./ER
9/82
21/90
Piccicacco
78%
0.22 [0.05-0.97]
progression
2/82
10/90
Kneidinger
20%
0.80 [0.35-1.82]
severe case
6/46
28/172
Ong
-75%
1.75 [0.23-13.0]
recov. time
4 (n)
14 (n)
Ong
-56%
1.56 [0.67-3.60]
hosp. time
4 (n)
14 (n)
Ong
-61%
1.61 [0.86-3.00]
viral time
4 (n)
14 (n)
Chew
-68%
1.68 [0.51-5.58]
progression
12 (n)
151 (n)
PLATCOV
Jittamala (RCT)
66%
0.34 [0.01-8.12]
hosp.
0/67
1/69
PLATCOV
Jittamala (RCT)
29%
0.71 [0.61-0.83]
viral rate
67 (n)
69 (n)
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Wang (RCT)
24%
0.76 [0.29-1.95]
death
8/71
7/47
Wang (RCT)
-48%
1.48 [0.45-4.88]
death
12/84
3/31
Olender
59%
0.41 [0.24-0.71]
death
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
death
14/25
24/26
ICU patients
Fried
61%
0.39 [0.15-0.99]
death
4/48
2,510/11,673
Fried
-37%
1.37 [0.81-2.30]
ventilation
11/48
1,956/11,673
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
Beigel (RCT)
45%
0.55 [0.36-0.83]
death
541 (n)
521 (n)
Beigel (RCT)
22%
0.78 [0.67-0.89]
no recov.
541 (n)
521 (n)
SOLIDARITY
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
El-Solh
29%
0.71 [0.52-0.97]
death
63/219
202/424
SARSTer
Flisiak
49%
0.51 [0.19-1.30]
death
5/122
17/211
SARSTer
Flisiak
58%
0.42 [0.13-1.18]
death
4/82
14/119
SARSTer
Flisiak
56%
0.44 [0.21-0.86]
no improv.
9/122
36/211
Garibaldi
20%
0.80 [0.46-1.41]
death
23/303
45/303
Garibaldi
35%
0.65 [0.53-0.78]
no improv.
52/303
80/303
Ullah
-100%
2.00 [0.67-5.94]
death
8/30
4/30
Ullah
-250%
3.50 [0.79-15.5]
ventilation
7/30
2/30
Yeramaneni
-24%
1.24 [0.11-14.2]
death
32 (n)
7,126 (n)
Goldberg
9%
0.91 [0.50-1.67]
hosp. time
29 (n)
113 (n)
Goldberg
0%
1.00 [0.92-1.09]
viral+
29 (n)
113 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
death
69/824
285/11,663
Tsuzuki
2%
0.98 [0.91-1.07]
ventilation
48/824
98/11,663
Tsuzuki
15%
0.85 [0.41-1.77]
progression
559/824
1,784/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Mahajan (RCT)
-112%
2.12 [0.41-10.8]
ventilation
4/34
2/36
Mulhem
-86%
1.86 [0.21-5.24]
death
1/8
515/3,211
Aghajani
19%
0.81 [0.46-1.46]
death
46 (n)
945 (n)
Elhadi (ICU)
-11%
1.11 [0.81-1.51]
death
14/21
267/444
ICU patients
Pourhoseingholi
-2%
1.02 [0.72-1.44]
death
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
death
203/1,491
777/4,676
Arch (PSM)
18%
0.82 [0.63-1.06]
death
140/1,502
565/4,728
Arch (PSM)
-68%
1.68 [1.19-2.34]
ventilation
106/1,498
153/4,602
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/42
4/57
Barrat-Due (DB RCT)
-36%
1.36 [0.29-6.39]
death
3/42
3/57
Barrat-Due (DB RCT)
55%
0.45 [0.05-4.20]
death
1/42
3/57
Ohl (PSM)
-6%
1.06 [0.83-1.36]
death
143/1,172
124/1,172
Ohl (PSM)
-100%
2.00 [1.33-3.02]
hosp. time
1,172 (n)
1,172 (n)
Madan
44%
0.56 [0.33-0.95]
death
23/398
27/260
Madan
66%
0.34 [0.12-0.96]
death
4/112
27/260
Madan
62%
0.38 [0.18-0.80]
death
9/226
27/260
Madan
-60%
1.60 [0.82-3.13]
death
10/60
27/260
Madan
31%
0.69 [0.37-1.29]
death
19/398
18/260
Madan
35%
0.65 [0.32-1.35]
death
14/398
14/260
Madan
48%
0.52 [0.21-1.31]
death
8/398
10/260
Madan
35%
0.65 [0.19-2.23]
death
5/398
5/260
Madan
13%
0.87 [0.20-3.86]
death
4/398
3/260
Kuno (PSM)
1%
0.99 [0.84-1.17]
death
214/999
216/999
Kuno (PSM)
0%
1.00 [0.80-1.24]
ventilation
140/999
140/999
Kuno (PSM)
-17%
1.17 [1.00-1.37]
ICU
260/999
222/999
Diaz
35%
0.65 [0.46-0.92]
death
33/286
173/852
Diaz
44%
0.56 [0.32-0.97]
death
286 (n)
852 (n)
DISCOVERY
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
DISCOVERY
Ader (RCT)
12%
0.88 [0.50-1.56]
death
21/414
24/418
DISCOVERY
Ader (RCT)
10%
0.90 [0.70-1.15]
7-point status
414 (n)
418 (n)
DISCOVERY
Ader (RCT)
-2%
1.02 [0.80-1.30]
7-point status
414 (n)
418 (n)
Mozaffari
12%
0.88 [0.81-0.96]
death
4,441/28,855
5,499/28,855
Mozaffari
24%
0.76 [0.69-0.83]
death
3,057/28,855
4,437/28,855
Schmidt (PSM)
-509%
6.09 [2.71-13.7]
severe case
43 (n)
434 (n)
Jamir (ICU)
8%
0.92 [0.55-1.55]
death
60/181
41/85
ICU patients
Mustafa
33%
0.67 [0.38-1.20]
death
16/200
29/244
CATCO
Ali (RCT)
12%
0.88 [0.72-1.07]
death
127/634
152/647
CATCO
Ali (RCT)
17%
0.83 [0.67-1.03]
death
117/634
145/647
CATCO
Ali (RCT)
21%
0.79 [0.40-1.58]
death
14/634
18/647
CATCO
Ali (RCT)
47%
0.53 [0.38-0.75]
ventilation
46/634
89/647
CATCO
Ali (RCT)
9%
0.91 [0.73-1.14]
no recov.
634 (n)
647 (n)
CATCO
Ali (RCT)
-11%
1.11 [1.01-1.23]
hosp. time
634 (n)
647 (n)
Kurniyanto
-460%
5.60 [2.32-13.5]
death
7/45
12/432
Siraj
53%
0.47 [0.35-0.62]
death
108/413
197/587
Salehi (ICU)
37%
0.63 [0.43-0.94]
death
17/40
57/85
ICU patients
Elec
19%
0.81 [0.38-1.69]
death
7/38
29/127
Elec
11%
0.89 [0.45-1.78]
ventilation
8/38
30/127
Elec
-72%
1.72 [1.11-2.66]
ICU
18/38
35/127
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
death
n/a
n/a
ICU patients
Malundo
-17%
1.17 [0.80-1.70]
death
24/115
197/1,100
Bowen
-57%
1.57 [1.25-1.97]
death
817 (n)
3,814 (n)
Raad
42%
0.58 [0.39-0.88]
death
n/a
n/a
Oku
-40%
1.40 [0.41-4.36]
death
3/46
8/172
Behboodikhah
38%
0.62 [0.30-1.30]
death
1,214 (n)
960 (n)
Hartantri
11%
0.89 [0.31-2.53]
death
n/a
n/a
Hartantri
24%
0.76 [0.33-1.77]
death
n/a
n/a
Alshamrani (PSM)
17%
0.83 [0.72-0.93]
death
137/246
725/1,078
Alshamrani (PSM)
4%
0.96 [0.90-1.00]
progression
215/246
984/1,078
Alshamrani (PSM)
-43%
1.43 [1.13-1.80]
ICU
245 (n)
995 (n)
Alshamrani (PSM)
7%
0.93 [0.81-1.05]
hosp. time
246 (n)
1,078 (n)
Mitsushima
-44%
1.44 [1.09-1.90]
death
n/a
n/a
Punzalan
-42%
1.42 [0.92-2.20]
death
47/224
26/176
Punzalan
-59%
1.59 [1.19-2.13]
progression
93/224
46/176
Kim
-1612%
17.12 [0.19-1565]
death
14/145
0/22
Aweimer
-13%
1.13 [0.93-1.37]
death
40/51
68/98
Intubated patients
Arfijanto
1%
0.99 [0.64-1.53]
viral+
17/44
46/118
Bavaro (PSW)
7%
0.93 [0.89-0.97]
severe case
120 (n)
211 (n)
Shamsi
-23%
1.23 [0.56-2.69]
death
8/53
16/130
Mozaffari (PSM)
25%
0.75 [0.68-0.83]
death
14,169 (n)
5,341 (n)
Mozaffari (PSM)
30%
0.70 [0.62-0.78]
death
14,169 (n)
5,341 (n)
Nadeem
-12%
1.12 [0.39-3.26]
death
12/96
4/36
Remdesivir COVID-19 outcomes
c19 early .org Sep 2023
Favors remdesivir
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit